浙江省肾综合征出血热疫苗流行病学研究  

Study on the Epidemiological Efficacy of Vaccines Against Hemorrhagic fever with renal syndrome

作　　者：龚震宇[1] 翁景清[1] 赵芝雅[1] 陈毓土[2] 祝阿根[2] 方春福[3] 傅桂明[1] 朱智勇[1] 陈恩富[1] 汪垂章 王玮[3] 雷林海[2] 

机构地区：[1]浙江省疾病预防控制中心传染病防制所,杭州310009 [2]龙游县疾病预防控制中心 [3]衢州市疾病预防控制中心

出　　处：《中国媒介生物学及控制杂志》2004年第4期312-314,共3页Chinese Journal of Vector Biology and Control

基　　金：国家"九五"医学科技攻关课题的一部分 (96 - 90 6 -0 3 - 1 3)

摘　　要：目的　观察姬鼠型高发疫区大面积人群接种肾综合征出血热 (HFRS)Ⅰ型灭活疫苗后的安全性、免疫原性和流行病学防病效果。方法　采用间接免疫荧光法 (IFAT)检测特异性IgG抗体 ,用微量细胞病变中和试验 (MCPENT)检测中和抗体滴度。结果　共接种 10 460人 ,全程接种者占 97.3 0 % ,对照 1615 9人。全程接种后 2周荧光抗体阳转率为10 0 % ( 67/67) ,中和抗体阳转率为 44 .44 % ,几何平均滴度分别为 72 .14和 4.63。加强免疫后血清抗体迅速回升 ,1年后又逐渐下降。预防接种后全身反应和局部反应轻微。接种组无发病 ,对照组发病 2 6例 ,死亡 3例。疫苗流行病学防病效果良好 ,人群保护率达 10 0 % ( 95 %CI :96.3 0 %～ 10 0 % )。结论　HFRS疫苗安全性良好 ,流行病学防病效果明显 ,取得了良好的经济效益和社会效益。Objective Observe the safety immunogenicity and epidemiological efficacy of HFRS vaccine in the focus population with high incidence of HFRS in Zhejiang province. Methods Immunofluorecent antibody assay was used in testing specific IgG antibody and Mcro-CPE method was used in testing the titer of neutralizing antibody.Results 10 460 people were vaccinated,97.30% of them completed their vaccination of full doses. 16 159 non-vaccinated people living in the same areas were used as the control group. Two weeks after the injection of the third dose,the sero-conversion rate by immunofluorecent antibody test(IgG) and neutralization test were 100%(67/67) and 44.44%,and the GMTs of them were 72.14 and 4.63 respectively. After reinforce,the rates of seroconversion of immunofluorecent antibody and neutralizing antibody were all going up,but all droped again after one year. The reaction of vaccine was little. The vaccinated group had no patient while the control group had 26 patients and 3 died. According to the six-year observation,the vaccine was effective,and his protection rate in population was 100%(95% CI :96.30%～100%). Conclusion HFRS vaccine was epidemiologically effective and safe.

关 键 词：浙江 肾综合征出血热 疫苗 流行病学 免疫 

分 类 号：R512.8[医药卫生—内科学]